Search results
Pfizer Failure in Duchenne Muscular Dystrophy Trial Leaves Field Open for a Rival
Barrons.com· 22 hours agoSECTORFOCUS BLOG A second failure of a late-stage trial testing a gene therapy to treat Duchenne ...
Pharma Stock Roundup: FDA Panel Endorses LLY's Donanemab, PFE's DMD Therapy Study Fails
Zacks via Yahoo Finance· 2 hours agoPfizer’s PFE phase III study of investigational gene therapy, fordadistrogene movaparvovec, for...
Sarepta’s stock gains after Pfizer’s Duchenne trial failure - Boston Business Journal
The Business Journals· 1 day agoSarepta Therapeutics, a Cambridge drugmaker known for its Duchenne muscular dystrophy treatments,...
Sarepta Jumps After Pfizer's Rival Gene Therapy Flops In Phase 3 Test
Investor's Business Daily· 19 hours agoSarepta stock jumped Thursday after Pfizer's rival gene therapy for Duchenne muscular dystrophy...
Pfizer's Duchenne Muscular Dystrophy Treatment Misses Endpoints
Morningstar· 2 days agoPfizer's gene therapy being developed to treat Duchenne muscular dystrophy missed its primary endpoint in a late-stage trial. The pharmaceutical ...
Pfizer’s gene-therapy trial failure boosts Sarepta’s stock
Market Watch· 1 day agogained 4% premarket on Thursday after a potential competitor to its gene therapy stumbled in a...
Pfizer Provides Update on Phase 3 Study of Investigational Gene Therapy for Ambulatory Boys with ...
Morningstar· 2 days ago(NYSE: PFE) today announced that CIFFREO, a Phase 3 global, multicenter, randomized, double-blind, placebo-controlled study evaluating the investigational mini-dystrophin gene therapy, fordadistrogene ...
Pfizer’s Phase III DMD gene therapy trial misses primary endpoint
Clinical Trials Arena via Yahoo Finance· 1 day agoPfizer has reported that its Phase III CIFFREO clinical trial of investigational mini-dystrophin...
Sarepta shares rise as Pfizer DMD trial misses goals By Investing.com
Investing.com· 24 hours agoThe firm's stance comes after Pfizer (NYSE:PFE) announced its phase 3 trial for a gene therapy...
Pfizer setback brings questions for Duchenne gene therapy ahead of Sarepta decision
BioPharma Dive via Yahoo Finance· 1 day agoThe failure of another trial adds to uncertainty around the benefits of the gene-based treatments,...